2. HMZ Pharmaceuticals has developed
MagnoTherm, a thermal magnetic
chemotherapeutic, for the treatment of
castration-resistant prostate cancer.
We hope MagnoTherm will become an
effective treatment option for prostate
cancer patients who have developed
resistance to the current drugs on the
market today.
We hope HMZ Pharmaceuticals will be able
to move this product from the laboratory
to market because it possesses numerous
advantages over current treatment options.
Product
Statement
3. The company is still in the early stages of research.
The in vitro studies are completed and animal
modeling is still in early stage.
All general lab work is conducted at rented laboratory
in Cambridge, MA. However, DFCI serves as the
company’s contract research organization because
they have the appropriate equipment for animal
models and MRI testing.
If the animal model research shows promising results,
the members will convert from a member-managed
llc to a manger-managed llc. This is the mode of
action because the members have limited experience
in business, marketing, finance, and law.
Business Concept
4. Magnotherm consists of Doxorubicin loaded
superparamagnetic nanoparticles which are
approximately 25nm in diameter
Superparamagnetic nature allows for enhanced
contrast properties that open potential applications
for magnetic resonance imaging.
They have the feasibility to trigger encapsulated
Doxorubicin release by the application of specific
radiofrequency and amplitude in an alternating
magnetic field and ensures the localized release of
drug at the tumor site.
Thus, using the concept of magneto chemotherapy,
Magno Therm can be used as an multifuntional
nanocarrier for combined therapy and imaging.
The Product
5. Serves as a theranostic agent that can be used for
both diagnosis and the treatment of the disease
Simultaneous diagnosis of tumor during the
treatment helps in reducing systemic toxic reactions
Targeted delivery of the drug also helps in avoiding
adverse side effects which are commonly seen with
other anticancer drugs
PEGylated coating of Magno Therm also makes these
nanoparticles water soluble and also shows better
dispersibility and enhanced long circulation
Features and benefits of
MagnoTherm
6. Primary goal of HMZ pharmaceuticals is to complete preclinical
studies of Magno Therm by the conclusion of 2015
Later we hope to get IND approval and start clinical trails in
collaboration with BSD Medical corporation.
They are developing a 3-D magnetic hyperthermia system which
also has MRI imaging function
This helps in targeted, triggered drug release and also helps in
giving real time imaging through MRI
Long term goals:
To create value for Magno Therm in the pharmaceutical market
with an anticipated share of 3-7 % of prostate cancer market
To improve quality of life of patients suffering from prostate
cancer by providing a safe and effective therapy
Goals and objectives
7. HMZ Pharmaceuticals is a member-managed
limited liability company that was formed in
Boston, Massachusetts at Northeastern
University.
A limited liability structure was the chosen
business structure as a result of numerous
advantages, such as protected assets, pass-
through taxation, and limited compliance
requirements.
Because all members are first time business
starters it is important that personal assets,
such as homes and savings accounts, are
protected in the event of business debts and
liabilities. In addition, this business structure
will ensure that the company will not pay
taxes at the business level, but instead on the
personal level. Since this company is newly
developed, the advantage of avoiding double
taxation is important.
Current Organization Structure
8. Manasa Jillella developed the idea of the magnetic thermal drug delivery system
while working in a nanomedicine laboratory at Northeastern University. She has
been working on iron oxide nanoparticles for triggered drug release for the past
year since developing the idea.. There she gained laboratory experience in the
research and development, but has worked on numerous cancer research based
projects as well.
Heather Goodwin received her Bachelor of Arts in Biology from College in 2011.
She also holds a minor in mathematics and chemistry.. Her experience in cancer
research dates back to 2010, when she began working in the Vidal laboratory at
Dana-Farber Cancer Institute in Boston, Massachusetts. As a student researcher
she studied Epstein-Barr virus associated cancers by examining disruptions in
normal protein interactions.
Shuang Zhang received her Bachelor of Science in Pharmaceutical Preparation
from China Pharmaceutical University. She also holds a minor in Business
Administration from China Pharmaceutical University. She has engaged in
multiple cancer research projects both in China and US. Currently, she works in
Northeastern University's Center for Pharmaceutical Biotechnology and
Nanomedicine. Her specialty is in nanosystems for cancer drug and siRNA
delivery. She has an extensive understanding on anticancer drug market and
marketing strategy.
Meet the Three Members
9. Board of Mangers: Five members with extensive
experience in pharmaceutical regulatory affairs,
research and development, finance, and sales &
marketing. Delegate the daily operations in the
company as outlined in an operating agreement.
Scientific Advisory Board: Eight members with
extensive experience in FDA law and regulations,
pharmacokinetics and dynamics, drug
development, clinical pharmacology, drug
metabolism, and toxicology. Offer expertise to
board of managers.
Employees: Approximately 10 employees with
backgrounds in health, science, and technology.
Meet the Future Team
Members/Owners:
Ms.Goodwin, Ms.Jillella, & Ms. Zhang
Board of Mangers:
responsible for the daily operations and decisions of
MagnoTherm
Employees
Board of Advisors:
Offer expertise pertaining
to a wide variety of
pharmacuetical
disciplines
Individual Equity
Ms. Goodwin 25.3%
Ms. Jillella 25.3%
Ms. Zhang 25.3%
Board of Managers 20%= 4% each
Advisory Board 4%= 0.5% each
Total = 100%
10. 12/17/2015
Market Summary
Global prostate cancer
market was
approximately $3 billion
in 2009.
The sales of prostate
cancer therapeutics
should exceed $8.1
billion, with a CAGR of
9.3%, by the year 2020
Source: Research and Markets. (2011). Global prostate cancer therapeutics market (2010 – 2020) (opportunity analysis, pipeline
assessment & market forecast). Retrieved from<http://www.researchandmarkets.com/reports/1957286/global_prostate_canc
er_therapeutics_market_2010>
• Market Size:
16. 12/17/2015
Resource and Requirements
Lab: A fully-established lab in a biotech incubator
with all lab equipment will be rented.
Animal test facility: All our animal work will be done in
Dana Farber Cancer Institute. No licenses and permit
for animal work will be needed for HMZ
Pharmaceuticals.
Manufacture facility: A contractor manufacturer will
be hired.
17. Exit Strategy
If advised by the financial advisor on the board of
managers, HMZ Pharmaceuticals will attempt to merge
with another company.
Disadvantages: Possible lack of control for existing staff
members and trouble blending the two company’s
cultures.
Advantages: Some members may still receive cash/stock,
resources form both companies, and some company
members may hold their job titles.
The members feel that the therapy will be extremely useful
in treating prostate cancer, if it is able to get to market.
Therefore, the efforts to expand and better the therapy
should not be wasted, but facilitated by other interested
individuals. 12/17/2015
18. BSD Medical Corporation
Serves as a potential corporation
partner.
They are developing a 3-
dimensional magnetic
hyperthermia system, which also
has MRI imaging function.
It could be useful in directing
MagnoTherm to target sites, for
inducing drug release, and for
giving real-time imaging through
MRI.
12/17/2015
20. 12/17/2015
Marketing and Sales
regional sales manager will
accommondate general marketing
guideline to region-specific plan.
internal distribution: technical
background sales representative,
instruct doctors to use the drug.
promotion starts early.
top physicians in clinical trial.
case collection surveys.
technology based marketing:
presentations, conference
sponsorship.
comprehensive customer service.
